Advertisement

Topics

Sanguine Company Profile

16:28 EST 20th November 2018 | BioPortfolio

Sanguine Corporation is a public company (OTC BB: SGNC) based in Pasadena, California, whose primary focus is the development of PHER-O2, a perfluorocarbon (PFC) emulsion with oxygen carrying properties that has immediate applications as an intravenous supplement to red blood cell function. The broad-based medical applications of PHER-O2 have strong market potential. Sanguine is a well-established organization with experts in the field of synthetic blood chemistry and development. Dr. Thomas C. Drees was a leader in the creation of Fluosol®, the only synthetic blood supplement approved to date for human use by the United States Food and Drug Administration (FDA). The FDA approved Fluosol for angioplasty use only in 1989 but Fluosol was withdrawn from the market in 1994 because of the difficulty of storing it frozen and then bringing it to ambient temperature prior to use.

Location

101 East Green Street, Suite 6
Pasadena
California
91105
United States of America

Contact

Phone: 801-746-3570
Fax: 801-532-1765
Email: info@sanguine-corp.com


News Articles [0 Results]

None

Drugs and Medications [0 Results]

None

PubMed Articles [7 Associated PubMed Articles listed on BioPortfolio]

Case report of a laboratory of medical analyses providing results of investigation of irregular antibodies that are non-compliant with the regulation in the Hauts-de-France state: Implications for haemovigilance.

Compliance with the European trauma guidelines: An observational single centre study.

The European trauma guidelines were developed to assist clinicians in the early phase of trauma management to diagnose and treat coagulopathy and bleeding. This study aimed to determine compliance wit...

Analysis of causes of destruction of labile blood products in health institutions: A multicentric study.

One of the tasks of haemovigilance correspondents in Health Institutions (HI) is to reduce the destruction of labile blood components (LBC). The objective of this study was to analyse in depth, five y...

Home blood transfusion in France: Benefits and development terms.

Patients with cancers or malignant homeopathies can suffer from chronic anemia and be regularly transfused in hospitals. Most of the time, their performance status is low. Few local structures current...

Inherited platelet disorders : Management of the bleeding risk.

Inherited platelet disorders are rare bleeding syndromes due to either platelet function abnormalities or thrombocytopenia which may be associated with functional defects. The haemorrhagic symptoms ob...

Clinical Trials [0 Results]

None

Companies [1 Associated Companies listed on BioPortfolio]

Sanguine

Sanguine Corporation is a public company (OTC BB: SGNC) based in Pasadena, California, whose primary focus is the development of PHER-O2, a perfluorocarbon (PFC) emulsion with oxygen carrying properti...

More Information about "Sanguine" on BioPortfolio

We have published hundreds of Sanguine news stories on BioPortfolio along with dozens of Sanguine Clinical Trials and PubMed Articles about Sanguine for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Sanguine Companies in our database. You can also find out about relevant Sanguine Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record